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ABSTRACT
It is well known that persistent infection with high-risk HPV (hr-HPV), mostly 
HPV-16 and 18, is the main cause of cervical cancer development. Manganese 
superoxide dismutase (MnSOD or SOD2) are highly expressed in different neoplasia. 
The present study investigated SOD2 protein expression and the presence of hr-HPV 
types in 297 cervical samples including non-neoplastic tissue, cervical intraepithelial 
neoplasia grade 3 (CIN3), squamous cell carcinoma (SCC) and adenocarcinoma (ADC). 
Strong SOD2 expression was significantly higher in ADC (82%) than CIN3 (52%) or 
SCC (64%). There was no association between SOD2 expression and HPV 16 and/or 
18 detection for every lesion analyzed. Binary Logist Regression revealed that strong 
SOD2 expression (OR: 27.50, 6.16-122.81) and HPV 16 and/or HPV 18 (OR: 12.67, 
4.04-39.74) were independently more associated with CIN3 than non-neoplastic 
cervix. Strong SOD2 expression (OR: 3.30, 1.23-8.86) and HPV 16 and/or HPV 18 (OR: 
3.51, 1.03-11.87) were independently more associated with ADC than SCC. Similar 
findings for SOD2 expression were observed by the Cochran Mantel-Haenszel test, 
controlling for HPV-16 and/or HPV 18. In conclusion, the expression of SOD2 was 
increased in CIN3 and SCC, and more increased in cervical ADC than in SCC. Strong 
SOD2 expression was statistically independent of the presence of HPV 16 and/or 18. 
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These findings suggest that the mitochondrial antioxidant system and HPV infection 
could follow independent pathways in the carcinogenesis of cervical epithelium and 
in the differentiation to SCC or ADC of the cervix.
INTRODUCTION
Cervical cancer is the second most common 
neoplasia in women, with estimated 500,000 cases 
occurring each year, globally resulting in >250,000 deaths 
[1–3]. Squamous cell carcinomas (SCC) represent 75 to 
85% of all cases of cervical cancer, while adenocarcinomas 
(ADC) represent 11 to 25% of cases and adenosquamous 
carcinomas represent 2 to 3% of cases [4–6].
Virtually 100% of cervical cancers are associated 
with human papillomavirus (HPV) infection [7]. Twelve 
HPV types have been consistently classified as high–
risk (hr-HPV) and all of them have been found in high-
grade squamous intraepithelial lesions (HSIL), squamous 
cell carcinoma (SCC) and adenocarcinoma (ADC) of 
the cervix; other 13 HPV types have been classified as 
probably/possibly carcinogen and have been found in 
HSIL, and less frequently in invasive cervical cancer [8]. 
In cervical cancer, the most prevalent type is HPV-16, 
followed by HPV-18; together, these viruses account for 
around 70% of SCC and over 80% of ADC cases [9, 10].
In parallel, several cervical carcinoma-derived 
cell lines have been shown to be resistant to TNF anti-
proliferative effect, suggesting that the acquisition of 
TNF-resistance may constitute an important step in 
HPV-mediated carcinogenesis. Analyzing the global 
transcription profile of normal and HPV-immortalized 
keratinocytes after TNFα treatment, using a microarray 
approach, manganese superoxide dismutase (MnSOD 
or SOD2) was identified as one of the differentially 
expressed genes in association with inflammatory 
response [11]. Superoxide dismutase proteins are highly 
expressed in different tumor types, and most of the current 
research efforts have been dedicated to understand their 
relation with the antioxidant system. Robust findings have 
shown that a subset of the SOD proteins is associated with 
cancer progression and metastatic phenotype [12–15]. 
These proteins are metalloenzymes that act in the cellular 
antioxidant system catalyzing the excess of superoxide 
anion to oxygen and hydrogen peroxide, which was 
thought to protect the cells from oxidative stress damage. 
Three distinct isoforms of SOD have been identified 
and characterized in mammals: copper-zinc superoxide 
dismutase (encoded by the SOD1 gene), manganese 
superoxide dismutase (encoded by the SOD2 gene) and 
extracellular superoxide dismutase (encoded by the 
SOD3 gene). Moreover, SOD2 is found exclusively in the 
mitochondrial matrix and is an evolutionary conserved 
enzyme in a variety of organisms [14].
The pathway by which SOD2 expression might 
contribute to cancer development is not clear, but some 
researchers have suggested that, as a pro-oxidant protein, 
it promotes the accumulation of hydrogen peroxide, 
which can further lead to activation of various oncogenic 
pathways [16, 17]. Such oxidative metabolic product was 
recently demonstrated to inactivate regulatory proteins, 
shifting the paradigm from being a simple by-product to 
an important oncogenic regulator in carcinogenesis [16, 
18]. In this context, one of the challenges is to understand 
under what circumstances hydrogen peroxide and, 
consequently, SOD2, plays a protective (antioxidant) or 
deleterious (pro-oxidant) role.
There is some evidence that oxidative stress and 
altered redox homeostasis might play a role as co-factors 
in cervical carcinogenesis [19, 20]. Termini et al. [20] 
evaluated SOD2 protein levels by immunohistochemistry 
in 331 cervical histological samples and observed that the 
frequency of SOD2-stained cells increases with cervical 
squamous disease severity, being particularly higher in 
ADC. Additionally, the SOD2 gene integrates a group of 
11 genes identified as a signature of 33-fold increased risk 
for predicting pelvic lymph node metastasis in cervical 
carcinoma [21].
In summary, HPV infection has been considered a 
necessary event for cervical cancer occurrence, although 
not sufficient to trigger its development. Other factors 
not directly dependent of these viruses should act for the 
cells to achieve the malignant phenotype; oxidative stress 
could be one of them and the SOD2 protein expression a 
marker of this condition. The goal of the present study was 
to analyze if SOD2 protein expression level is associated 
with HPV infection, focusing on the 16 and 18 types, in 
ADC, SCC and cervical intraepithelial neoplasia 3 (CIN3) 
samples.
RESULTS
HPV prevalence and type distribution according to 
the histopathological diagnosis are presented in Table 1. 
The overall prevalence of HPV was 83.6% in ADC (61 out 
of 73), 93.4% in SCC (57 out of 61) and 90.3% in CIN3 
(93 out of 103). Most of the cases were positive for high-
risk HPV types. The prevalence of HPV in women with 
non-neoplastic diagnosis (cervicitis and normal tissues) 
was 43.4% (26 out of 60). Women with non-neoplastic 
diagnosis that were included in the study due to suspicion 
of high-grade lesion were more likely to have detectable 
HPV-DNA, which probably justifies the prevalence 
of HPV in this group. Among the 26 women with non-
neoplastic diagnosis that tested positive for HPV DNA, 
half was infected with low-risk HPV types (6, 11, 44 and 
74). HPV-16 and/or HPV-18 were detected in 6.7% of 
non-neoplastic samples, 49.5% of cases of CIN3, 68.8% 
of cases of SCC and 69.8% of cases of ADC.
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Figure 1 shows the association between HPV and 
the occurrence of cervical lesions, considering only the 
cases in which high-risk HPV types were detected. HPV-
16/18 detection was significantly associated with ADC 
(p < 0.00001) and SCC (p = 0.02) when compared with 
CIN3. In addition, these two viral types were significantly 
more associated with ADC than SCC (p = 0.02).
The expression pattern of SOD2 protein was 
determined in the different histopathological samples 
using the non-neoplastic tissues as the control. As a general 
rule, SOD2 positive cells display a granular cytoplasmic 
staining pattern. Overall, a strong cytoplasmic SOD2 
staining was observed in CIN3, SCC and ADC throughout 
the lesion, while no staining was observed in the stromal 
cells. However, in some cases, SOD2 expression was also 
observed in inflammatory cells infiltrating both epithelium 
and stroma. Representative examples of SOD2 staining in 
CIN3, SCC and ADC are presented in Figure 2.
Most samples of non-neoplastic epithelia and 
normal glandular cells presented weak or negative staining 
for SOD2. Strong SOD2 expression (>50% positive 
cells) was observed in 3%, 52%, 64% and 82% of non-
neoplastic samples, CIN3, SCC and ADC, respectively 
(Figure 3). Figure 4 shows that strong SOD2 expression 
was significantly higher in ADC, SCC and CIN3 (p < 
0.00001) when compared with non-neoplastic tissues and 
was significantly higher in ADC than in CIN3 (p < 0.0001) 
and SCC (p = 0.02). No statistical difference was found 
between SCC and CIN3 (p=0.15).
Analyzing the SOD2 expression and HPV-16 and/
or 18 for every histological diagnosis no association was 
observed between strong SOD2 expression and HPV-
16/18 detection when compared with cervical samples 
positive for other high risk HPV types (Table 2).
Strong SOD2 expression and HPV-16 and/or 18 
positivity were identified as independent variables using 
binary logistic regression in an interdiagnosis comparison. 
Strong SOD2 expression (OR: 27.50, 95% CI: 6.16-
122.81) and HPV-16 and/or HPV 18 (OR: 12.67, 95% 
CI: 4.04-39.74) were independently associated with CIN3 
when compared with non-neoplastic diagnosis. Strong 
SOD2 expression (OR: 3.30, 95% CI: 1.23-8.86) and 
HPV-16/18 positivity (OR: 3.51, 95% CI: 1.03-11.87) 
were also independently associated with ADC when 
compared with SCC. Similar findings were observed for 
ADC when CIN3 was considered as reference. Strong 
SOD2 expression was not associated with SCC when 
compared with CIN3 (OR:1.54, 95% CI: 0.77-3.10). The 
Cochran Mantel-Haenszel test showed similar findings for 
strong SOD2 expression in all interdiagnosis comparisons, 
controlling for HPV-16 and/or HPV 18 (Table 3).
DISCUSSION
The role of SOD2 in cancer initiation and 
progression is not well understood. In vitro studies have 
demonstrated that overexpression of members of the 
SOD family correlates with increased cell differentiation, 
decreased cell growth and proliferation, and reversion of 
malignant phenotype [22]. Reduction of oxidative stress 
by increasing SOD2 levels might prevent DNA injury and 
consequently cancer development. Indeed, a protective 
role of SOD2 against tumor progression in transformed 
cell lines has been reported [23–25]. On the other hand, 
SOD2 activity might preclude the accumulation of H2O2, 
a component of reactive oxygen species (ROS), preventing 
programmed cell death or necrosis onset, thus favoring the 
malignant phenotype [12, 15, 26].
Table 1: Prevalence of HPV according to histological diagnosis
HPV detection
Diagnosis
All cervical samples n(%)Non-neoplastic CIN3 SCC ADC
n(%) n(%) n(%) n(%)
HPV-16 and/or 18* 4(6.7) 51(49.6) 42(68.8) 51(69.8) 148(49.8)
Other high-risk 
HPV * 9(15.0) 42(40.7) 14(23.0) 4(5.4) 69(23.2)
Only low-risk 
HPV 13(21.6) - 1(1.6) 6(8.3) 20(6.7)
HPV-positive 26(43.3) 93(90.3) 57(93.4) 61(83.6) 237(79.8)
HPV-negative 34 (56.7) 10 (9.7) 4 (6.6) 12 (16.4) 60 (20.2)
Total 60(100) 103(100) 61(100) 73(100) 297(100)
CIN3: cervical intraepithelial neoplasia grade 3; SCC: squamous cell carcinoma; ADC: adenocarcinoma. *Single or multiple 
infections.
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A recent review on SOD2 and carcinogenesis 
summarized that ROS largely originating in the 
mitochondria play essential roles in the metabolic and 
(epi) genetic reprogramming of cancer cell evolution 
towards more aggressive phenotypes. Therefore, there 
is likely a dichotomy where SOD2 can be considered a 
protective antioxidant reducing superoxide, as well as a 
pro-oxidant factor during cancer progression, with these 
effects depending on the accumulation and detoxification 
of H2O2 [18]. Nevertheless, the current understanding 
converges to the consensus that cancer cells exhibit a wide 
range of metabolic phenotypes that accumulate excessive 
ROS in relation to normal cells. Such ROS accumulation 
induces cellular damage that may promote cancer 
development as well as its metabolic phenotype [13-15, 
27]. In fact, most of the studies about SOD2 expression 
and cancer have shown that overexpression of this enzyme 
is associated with the presence of metastases and poor 
prognosis in many malignancies, such as lymphomas [28, 
29], glioblastoma [30], bladder [31], lung [32], colorectal 
[33], breast [34], penile [35], gastric [36], esophageal [37] 
and oral cancer [38].
In relation to cervical cancer and its precursor 
lesions, Termini et al. [20] examined the expression 
of SOD2 in a set of cervical samples, including low-
grade squamous intraepithelial lesion (LSIL), HSIL, 
SCC and ADC. Those authors observed that HSIL and 
invasive cancers exhibited higher SOD2 levels than 
LSIL and, in most LSIL samples, they observed no or 
low SOD2 expression. On the other hand, a significant 
percentage of HSIL, SCC and ADC were included in the 
>50% stained cell category, exhibiting predominantly 
cytoplasmic granular deposits in all the layers of the 
epithelium. However that study did no mention about 
patterns of SOD2 expression and HPV infection for any 
circumstances.
Our study showed that the detection rate of HPV 16 
and/or 18 increased with the squamous lesion severity, and 
this finding was expected [8]. Strong SOD2 expression 
was higher in CIN3 in relation to non neoplastic tissue, 
but in relation to SCC the difference was not statistically 
significant. This finding cannot be directly compared with 
those of Termini et al. [20] that showed little bit higher 
percentage of cases with strong SOD2 expression for 
HSIL than for LSIL, but the difference was not statistically 
significant. Even though HSIL classification includes 
CIN3, it also includes CIN2, which may have an LSIL 
phenotype [39].
Although the HPV types 16 and 18 are more 
typically prevalent in more severe cervical neoplastic 
lesions, such as strong SOD2 expression, no association 
was observed between strong SOD2 expression and 
HPV-16 and/or 18 in non-neoplastic tissue, CIN3, SCC 
or ADC samples. This information is new and suggests 
that SOD2 and HPV-16 and/or 18 infections could act 
in the carcinogenic process through different pathways, 
and not as co-factors. Additionally, this study showed 
that, controlling for the presence of HPV-16 and/or 18, 
strong SOD2 expression was significantly associated with 
CIN3 in relation to non-neoplastic cervical tissue, but 
Figure 1: Association between high-risk HPV types and histological diagnosis of Cervical Intraepithelial Neoplasia 
(CIN3), Squamous Cells Carcinoma (SCC) and Adenocarcinoma (ADC). HPV-16 and/or 18 were compared with other high 
risk HPV types. Statistical analysis was performed by X2 test.
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Figure 2: Representative examples of SOD2 immunohistochemical expression in cervical samples. SOD2 expression 
levels in CIN3 (A, B), SCC (C, D) and ADC (E, F) samples were determined by immunohistochemistry. Samples with less (A, C, E) or 
more (B, D, F) than 50% of the cells exhibiting SOD2 expression are presented. CIN3 - Cervical Intraepithelial Neoplasia grade 3, SCC 
- Squamous Cells Carcinoma ADC- Adenocarcinoma. (Bars: 100 μm). Non-neoplastic diagnoses with less or more than 50% of the cells 
exhibiting SOD2 expression are inset respectively in A and B.
Figure 3: Strength of SOD2 staining according to histological diagnosis. Expression was classified as negative or weak (<10% 
positivity), moderate (10–50% positivity) or strong (>50% positivity) in samples of cervical intraepithelial neoplasia (CIN3), squamous 
cells carcinoma (SCC) and adenocarcinoma (ADC).
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there was no association between CIN3 and SCC. These 
findings are also new and reinforce the hypothesis that 
SOD2 could have a relevant and independent role in CIN3 
development, but the data available do not support this 
assumption for the CIN3 progression to SCC.
Cervical ADC, in relation to SCC, occurs more 
frequently in younger and Caucasian women, and is 
generally associated with worse prognosis [40, 41]. 
The incidence of invasive cervical cancer has been 
decreasing in recent years. Nevertheless, cervical ADC 
(i.e., adenocarcinoma and adenosquamous carcinoma) 
stands out because its incidence among younger women 
has increased in more developed countries, even those 
with widespread screening programs [42]. In the United 
States, the proportion of ADC relative to SCC and to all 
cervical cancers doubled between 1973 and 1996, and the 
rate of ADC per population at risk also increased over this 
period [43]. In worldwide studies, HPV types 16 and 18 
were present in, respectively, 56.8% and 11.6% of women 
with invasive SCC, and in 36.1% and 34.9% of women 
with ADC. However, cervical ADC and SCC differ not 
only with respect to the distribution of HPV types but also 
with respect to intratypic variants; non-European HPV-16 
and HPV-18 variants are more commonly seen in ADC 
[44–46].
This study showed that SOD2 expression is 
especially higher in ADC in relation to other cervical 
samples, including SCC. Eighty-two percent of ADC and 
64% of SCC cases revealed strong SOD2 expression, and 
no ADC cases showed negative or moderate expression. 
Termini et al. [20] described similar findings, with strong 
SOD2 expression in 66% of ADC and 40% of SCC. 
Our study also showed that, controlling for the presence 
of HPV-16 and/or 18, strong SOD2 expression was 
significantly associated with ADC in relation to CIN3 and 
SCC.
The pathway by which some types of HPV or 
variants could be associated with ADC or SCC is not clear. 
Also, no information was found in the literature about the 
SOD2 expression in non-neoplastic glandular epithelium 
of the cervix. This study indicates that the oxidative stress 
is higher in the ADC and the antioxidant system is strongly 
activated. At this point, it seems not possible to indicate 
how much the oxidative stress is an agent promoting the 
carcinogenesis or how much it is consequence of the cancer 
progression. The H2O2 produced in the mitochondria seems 
indispensable for hypoxic adaptation and energetic and/or 
metabolic homeostasis, and, therefore, it seems relevant 
to elucidate how much this process depends on and is 
controlled by SOD2. In this way, the better understanding 
of redox hubs in the mitochondria will likely lead to 
new and improved therapeutics of a number of diseases, 
including cancer [27, 47].
In conclusion, our results showed that the expression 
of SOD2 was increased in CIN3 and SCC, and more 
increased in cervical ADC than in SCC, and this pattern 
of SOD2 expression was statistically independent of the 
presence of HPV 16 and/or 18, the most prevalent types 
in the cervical cancer. These findings suggest that the 
mitochondrial antioxidant system and HPV infection 
Figure 4: Comparative analysis of SOD2 expression in cervical samples. SOD2 staining was determined as strong when 
positive in more than 50% of cells and weak or moderate when positive in less than 50% of cells. Strong SOD 2 expression was associated 
with cervical intraepithelial neoplasia and carcinoma when compared to non-neoplastic tissues. It was also associated with Adenocarcinoma 
(ADC) when compared to Squamous Cells Carcinoma (SCC) and Cervical Intraepithelial Neoplasia (CIN3). Statistical analysis was 
performed by the Fisher Exact test.
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could follow independent pathways in the carcinogenesis 
of cervical epithelium and in the differentiation to SCC or 
ADC of the cervix.
MATERIALS AND METHODS
Ethics statement
All tissue samples were originally collected for 
diagnostic purposes and were thoroughly anonymized 
before the use in this study. This study was approved 
by the State University of Campinas ethics committee 
(Protocol No. 04500146000-10). The institutional ethics 
committee waived the need for signed consent because 
this was a risk-free retrospective study and it was no 
longer possible to contact many of the enrolled women.
Tissue samples
Case selection was based on pathology reports 
obtained from 2005 from women consecutively attended to 
at the Women’s Hospital Prof. Dr. José Aristodemo Pinotti, 
State University of Campinas, Brazil. Haematoxylin-eosin 
(H&E) paraffin-embedded sections were reviewed and the 
best representative samples were identified. Specimens 
were obtained by punch biopsies, large loop excisional 
cervical procedures, cones or hysterectomies. All women 
with non-neoplastic lesion and CIN3 had previous 
abnormal Pap test and they had undergone conization or 
Table 3: SOD2 expression and HPV-16/18 detection in cervical neoplasias: an interdiagnosis comparison
Compared diagnoses n
Binary Logistic Regression Mantel Haenszel Test*
Strong SOD2 
expression** HPV 16/18 Strong SOD2 expression
**
OR (95% CI) OR (95% CI) OR (95% CI)
CIN3 vs Non-
neoplastic 106 27.50 (6.16-122.81) 12.67 (4.04-39.74) 13.95 (1.74-111.11)
SCC vs CIN3 149 1.54 (0.77-3.10) 2.35 (1.12-4.91) 1.54 (0.76-3.13)
ADC vs CIN3 148 3.86 (2.48-16.28) 4.06 (3.35-32.24) 5.85 (2.32-14.69)
ADC vs SCC 111 3.30 (1.23-8.86) 3.51 (1.03-11.87) 2.94 (1.09-7.89)
CIN3: Cervical Intraepithelial Neoplasia grade 3; SCC: Squamous Cell Carcinoma; ADC: Adenocarcinoma; hr-HPV: High-
risk HPV.*Controlling for HPV 16/18. **Positive in 50% or more cells.
Table 2: SOD2 expression in cervical samples with high-risk HPV types according to the diagnosis
Diagnosis Hr-HPV type
Level of SOD2 expression*
p-value**Strong Negative/weak/ moderate
n(%) n(%)
Non-neoplastic HPV-1618 0(0) 4(100) -
Other hr-HPV 0(0) 9(100)
CIN 3 HPV-16/18 27(56.2) 24(53.3) 0.84
Other hr-HPV 21(43.8) 21(46.7)
SCC HPV-16/18 30(83.3) 12(60.0) 0.10
Other hr-HPV 6(16.7) 8(40.0)
ADC HPV-16/18 44(91.7) 7(100%) 1.00
Other hr-HPV 4(8.3%) 0(0%)
CIN3: cervical intraepithelial neoplasia grade 3; SCC: squamous cell carcinoma; ADC: adenocarcinoma; hr-HPV: high-risk 
HPV. *SOD2 expression was determined as strong when positive in 50% or more cells. **Comparison between samples with 
HPV-16/18 and samples with other types of hr-HPV by Fischer Exact Test.
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loop excision of transformation zone of the cervix due to 
suspicion of squamous high-grade lesion.
Fixed and paraffin embedded tissues were cut into 
3-μm sections and stained with H&E for histological 
analysis and selection of the appropriate tissue area for 
further investigations. This study included 297 cervical 
samples: 73 ADC, 61 SCC, 103 CIN3 and 60 non-
neoplastic cervical tissue.
The sample size estimation was based on the data 
from the Termini et al. study of SOD2 expression in 
different stages of cervical neoplasia [20]. Those authors 
used two sided 95% confidence intervals and statistical 
power of 80%, and reported strong SOD2 cellular staining 
(positive in >50% of cells) in 40% of SCC cases and in 
65.4% of cervical ADC cases; considering both SCC 
and ADC, that study used a total of 122 cases for Kelsey 
methods and 120 cases for Fleiss methods. In the present 
study, the total number of samples of these two tumor 
types was 134.
HPV detection and genotyping
Cervical specimens with a confirmed histological 
diagnosis were analyzed for the presence of HPV DNA. 
Paraffin sections were systematically obtained from 
each block using a sandwich method (3-μm sections for 
H&E staining were taken immediately before and after 
the sections used for HPV DNA analysis). Total DNA 
was extracted using a proteinase K lysis procedure, as 
previously described [26]. The microtome blade was 
changed after each block was cut and all the surrounding 
area and apparatus were cleaned with xylene and ethanol 
after processing to avoid contamination between samples.
The Innogenetics (Gent, Belgium; now Fujibio) 
INNO-LiPA SPF-10 HPV Genotyping Extra assay was 
used according to the manufacturer’s instructions. This 
version of the assay allows the simultaneous and separate 
detection of 15 high-risk HPV types (HPV-16, -18, -31, 
-33, -35, -39, -45, -51, -52, -56, -58, -59, -66, -68, and -70) 
and 10 low-risk HPV types (HPV-6, -11, -34, -40, -42, -43, 
-44, -53, -54, and -74).
Immunohistochemical SOD2 detection
After deparaffinization in xylene and rehydration 
in alcohol, antigen retrieval was performed by 
incubation in boiling 10mM citrate buffer, pH 6.0, 
for 20 minutes. Samples were incubated with an anti-
SOD2 mouse polyclonal antibody (ab13533, Abcam, 
Cambridge, UK), at a 1:1500 dilution in 10% horse 
serum phosphate buffered saline solution for 18 hours at 
4°C. Immunohistochemistry for SOD2 was performed 
according to Polymer Detection System (NovolinkTM 
Max Polymer detection Systems, Leica Biosystems, 
Newcastle, UK), as described elsewhere [20]. Sections 
derived from high-grade serous adenocarcinoma of the 
ovary were used as a positive control for SOD2 expression 
and were incubated in the absence or in the presence of 
anti-SOD2 antibody.
Evaluation of SOD2 expression
The immunohistochemical assays were evaluated 
considering the percentage of stained epithelial cells. 
SOD2 expression was categorized based on cytoplasm 
positive reactions, as previously reported [20]; samples 
were classified as “negative/weak” (<10% stained cells), 
“moderate’ (10–50% stained cells) or “strong” (>50% 
stained cells). Immunohistochemical evaluation was 
performed independently and blindly by three observers 
(SHR-S, AL-F, LALA-A); discordant findings were 
discussed among them to achieve a consensus score.
Statistical analysis
All statistical analyses were performed with the 
Statistical Package for Social Sciences (SPSS) 15.0 
software. Samples diagnosed as non-neoplastic were used 
as the reference category for comparisons with CIN3, SCC 
and ADC. Furthermore, samples diagnosed as CIN3 and 
SCC were used as reference for ADC analysis. For the 
statistical analyses, the SOD2 expression was scored as 
less or equal to 50% of stained cells (negative to moderate 
expression) or more than 50% of stained cells (strong 
expression). The analysis of SOD2 expression and HPV-
16 and/or 18 for every histological diagnosis was made 
using Fischer Exact Test.
The association between SOD2 expression and 
HPV types in CIN3, SCC and ADC samples, in an 
interdiagnosis comparison, was analyzed. For this 
purpose, binary logistic regression was used to estimate 
the probability of a binary response (different stages of the 
cervical neoplastic lesions) taking as predictor variables 
the SOD2 expression and HPV types. The Cochran 
Mantel-Haenszel test was used to confirm the strong 
SOD2 expression as a predictor variable for the different 
stages of neoplastic lesions, controlling for presence of 
HPV 16 and/or 18.
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